Patents by Inventor Ruben ALVAREZ RODRIGUEZ
Ruben ALVAREZ RODRIGUEZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115611Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.Type: ApplicationFiled: September 20, 2023Publication date: April 11, 2024Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
-
Publication number: 20240058447Abstract: Provided herein are methods employing various fusion constructs in T cell therapy. The fusion constructs allow for one to reduce, to the point of full removal if desired, the use of IL-2 that would otherwise accompany an in vivo T cell therapy.Type: ApplicationFiled: May 24, 2023Publication date: February 22, 2024Inventors: Owen R. Moon, Rubén Alvarez-Rodríguez, John Bridgeman
-
Patent number: 11793834Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.Type: GrantFiled: December 11, 2019Date of Patent: October 24, 2023Assignee: Kite Pharma, Inc.Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
-
Publication number: 20230331855Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.Type: ApplicationFiled: March 3, 2023Publication date: October 19, 2023Inventors: Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ, Alice BAKKER, Lawren WU, Tara ARVEDSON
-
Publication number: 20230146195Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: ApplicationFiled: November 14, 2022Publication date: May 11, 2023Inventors: Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ, Jonathan BELK
-
Publication number: 20230124464Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to FLT3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the FLT3 antigen binding molecules and engineered immune cells.Type: ApplicationFiled: May 23, 2022Publication date: April 20, 2023Inventors: Alice BAKKER, Lawren WU, Tara ARVEDSON, Jed J. WILTZIUS, Ruben Alvarez RODRIGUEZ
-
Patent number: 11505613Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: GrantFiled: September 12, 2019Date of Patent: November 22, 2022Assignee: Kite Pharma, Inc.Inventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Jonathan Belk
-
Publication number: 20210277132Abstract: The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: ApplicationFiled: May 24, 2021Publication date: September 9, 2021Inventors: Ruben ALVAREZ RODRIGUEZ, Armen MARDIROS
-
Patent number: 11046775Abstract: The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: GrantFiled: February 14, 2018Date of Patent: June 29, 2021Assignee: Kite Pharma, Inc.Inventors: Ruben Alvarez Rodriguez, Armen Mardiros
-
Publication number: 20210163621Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.Type: ApplicationFiled: April 10, 2019Publication date: June 3, 2021Applicants: AMGEN INC., KiTe Pharma, Inc.Inventors: Michael John Giffin, Melissa THOMAS, Christopher MURAWSKY, Ryan B. CASE, Lawren WU, Jed J. WILTZIUS, Ruben Alvarez RODRIGUEZ, Jun FENG
-
Publication number: 20210040449Abstract: The disclosure provides a method of generating modified T cells from engineered stem cells for use in an autologous or allogeneic setting for engineered immunotherapy. The knockout of endogenous TCR or HLA expression allows for engineering of modified pluripotent stem cells that reduce or eliminate the risk of Graft versus Host Disease (GVHD), provide resistance to elimination by a recipient's T cells and NK cells, and allow for controllable T cell activity. Thus, this method allows the development of T cells with reduced immune reactivity.Type: ApplicationFiled: February 15, 2019Publication date: February 11, 2021Inventors: Eric GSCHWENG, Rajul JAIN, Yong OUYANG, Arianne PEREZ GARCIA, Margo ROBERTS, Ruben ALVAREZ RODRIGUEZ, Drake SMITH, Xingliang ZHOU
-
Publication number: 20200246382Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.Type: ApplicationFiled: December 11, 2019Publication date: August 6, 2020Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk
-
Patent number: 10689450Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: GrantFiled: March 31, 2017Date of Patent: June 23, 2020Assignee: KITE PHARMA, INCInventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Jonathan Belk
-
Publication number: 20200115457Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.Type: ApplicationFiled: October 21, 2019Publication date: April 16, 2020Inventors: Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ, Alice BAKKER, Lawren WU, Tara ARVEDSON
-
Publication number: 20200109209Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: ApplicationFiled: September 12, 2019Publication date: April 9, 2020Inventors: Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ, Jonathan BELK
-
Patent number: 10597456Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.Type: GrantFiled: March 31, 2017Date of Patent: March 24, 2020Assignees: AMGEN INC., KITE PHARMA, INC.Inventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Alice Bakker, Lawren Wu, Tara Arvedson
-
Publication number: 20180230224Abstract: The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: ApplicationFiled: February 14, 2018Publication date: August 16, 2018Inventors: Ruben ALVAREZ RODRIGUEZ, Armen MARDIROS
-
Publication number: 20170283504Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: ApplicationFiled: March 31, 2017Publication date: October 5, 2017Inventors: Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ
-
Publication number: 20170283500Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.Type: ApplicationFiled: March 31, 2017Publication date: October 5, 2017Inventors: Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ